LUMEN BIOSCIENCE
Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases.
LUMEN BIOSCIENCE
Industry:
Biopharma Biotechnology Life Science
Founded:
2017-04-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.lumen.bio
Total Employee:
51+
Status:
Active
Contact:
206-899-1904
Total Funding:
47.5 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Google Google DNS Google Domains Google Cloud DNS NetSuite Mail
Similar Organizations
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Castle Creek Biosciences
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Lumen Bioscience
U.S. Army Medical Research & Development Command
U.S. Army Medical Research & Development Command investment in Grant - Lumen Bioscience
Avista Development
Avista Development investment in Series B - Lumen Bioscience
WestRiver Group
WestRiver Group investment in Series B - Lumen Bioscience
Columbia Pacific Advisors
Columbia Pacific Advisors investment in Series B - Lumen Bioscience
Bioeconomy Capital
Bioeconomy Capital investment in Series B - Lumen Bioscience
US Department of Energy
US Department of Energy investment in Grant - Lumen Bioscience
Avista Development
Avista Development investment in Series A - Lumen Bioscience
Bioeconomy Capital
Bioeconomy Capital investment in Series A - Lumen Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2020-09-10 | Lumen hires Spigarelli as CMO to lead infectious disease pipeline work |
Official Site Inspections
http://www.lumen.bio Semrush global rank: 8.73 M Semrush visits lastest month: 261
- Host name: 23.185.0.1
- IP address: 23.185.0.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lumen Bioscience"
About - Lumen Bioscience
Lumen’s patented technology allows us to use the well-known ... Bioscience. He joins Lumen following six years as Medical Director at Parexel, an industry leading clinical research …See details»
Lumen Bioscience Details 2022 Company and Facilities Growth, …
Jan 5, 2023 Lumen also made strong progress in the CARB-X-funded program to develop a broad antibody cocktail offering protection against most clinically important strains of ETEC …See details»
Lumen Bioscience - Crunchbase Company Profile
Lumen Bioscience develops and manufactures biologic drugs and vaccine candidates using a technology platform that allows for rapid and cost-effective …See details»
CARB-X is funding Seattle-based Lumen Bioscience to develop a …
The World Health Organization (WHO) estimates that 700,000 people die each year from drug-resistant infections, including 35,000 in the US and 33,000 in Europe. ... [email protected]. …See details»
Seattle based Lumen Bioscience is using the cyanobacteria …
Dec 12, 2024 CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and manufacturing protein-based medicines. …See details»
Lumen Bioscience - The Org
Lumen unlocks the full potential of biologic drugs, whose promise has been held back by the lack of scalable technology. Lumen's goal is to transform the way such drugs are developed, what …See details»
Lumen Bioscience - Biotech Careers
Lumen Bioscience is a Seattle-based synthetic biology company focused on the development of the blue-green algae Spirulina as an industrial scale production platform. Lumen has …See details»
Lumen Bioscience - Devex
Lumen Bioscience is a Seattle-based synthetic biology company focused on the development of the blue. ... Type of organization. Goods Supplier Service Providers . United States .See details»
Lumen Bioscience Company Profile - Office Locations ... - Craft
Lumen Bioscience is a biotech company developing biologic oral antibody therapeutics. It utilizes a patented biologic drug platform to provide drugs for the treatment of clostridium difficile, …See details»
Science - Lumen Bioscience
Bio Engineering. A gene encoding the therapeutic molecule (for example, an antibody protein or cytokine) is introduced into the spirulina chromosome. 03. ... Time, risk, and money are the three wild cards of drug development. Lumen’s …See details»
Working At Lumen Bioscience: Company Overview and Culture
Mar 14, 2024 Organization Type. Private. Social Media. Lumen Bioscience is a Seattle-based syn-bio company developing of the blue-green algae Spirulina as an industrial scale …See details»
Lumen Bioscience Details 2022 Company and Facilities Growth, …
Jan 5, 2023 LMN-301 for Covid-19 – In 2022, Lumen Bio's Covid-19 funding consortium expanded to include BARDA and the Bill & Melinda Gates Foundation. Strong preclinical data …See details»
Lumen Bioscience - Overview, News & Similar companies
May 17, 2023 Lumen Bioscience awarded $16.2 million in DoD funding to advance LMN-201 through late-stage trials Orally delivered biologic drug to treat and prevent C. difficile infection …See details»
Lumen Bioscience Details 2022 Company and Facilities Growth
Jan 5, 2023 Lumen also made strong progress in the CARB-X-funded program to develop a broad antibody cocktail offering protection against most clinically important strains of ETEC …See details»
Lumen Bioscience - Work in biotech
Lumen Bioscience is developing new drugs for highly prevalent diseases. Many highly prevalent diseases have proven impossible to treat with traditional drug-making tools, despite much …See details»
Lumen Bioscience Company Information - Funding, Investors, and …
Get information on funding, investors, industries, and more for Lumen Bioscience. See Lumen Bioscience company profile and funding data.See details»
Lumen Bioscience - Funding, Financials, Valuation & Investors
Lumen Bioscience is funded by 9 investors. U.S. Department of Defense and U.S. Department of Defense are the most recent investors. Lumen Bioscience has a post-money valuation in the …See details»
Lumen Bioscience's LMN-201 Achieves 100% Initial C. difficile …
2 days ago About LMN-201 and Lumen Bio LMN-201 is orally delivered (capsules; no enema or "bowel cleanse" required) and highly scalable, allowing for much broader potential use in …See details»
Cognition Live Article on RePreve Trial - Lumen Bioscience
2 days ago It is made with Lumen’s proprietary spirulina-based GMP manufacturing system. In a previous interview with Contagion , Lumen Bioscience cofounder and CEO Brian Finrow …See details»
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in
3 days ago Strong potential to disrupt market for treatment of C. diff infections RePreve Trial main cohort now recruiting Seattle, WA – April 3, 2025 – In a landmark achievement for its …See details»